| Literature DB >> 34689148 |
Danni He1,2, Xiuxiu Lu3, Wei Li3, Yuanyuan Wang4, Ning Li3, Yuanmei Chen2, Lipeng Zhang2,5, Wenquan Niu1, Qi Zhang2.
Abstract
BACKGROUND We designed an association study among 267 cases of children with sepsis and 283 healthy controls, by genotyping 9 variants in the VDR gene. MATERIAL AND METHODS This was a hospital-based, case-control, genetic association study. In addition to 3 genetic modes of inheritance, haplotype and interaction analyses were employed to examine the prediction of VDR gene for pediatric sepsis. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI). RESULTS Two variants in the VDR gene, rs2107301 and rs2189480, were found to play a leading role in susceptibility to sepsis in children. The mutant homozygotes of rs2107301 (CC) and rs2189480 (CC) were associated with a reduced risk of sepsis compared with the corresponding wild homozygotes (OR: 0.44 and 0.43, 95% CI: 0.21-0.92 and 0.23-0.81, p: 0.03 and 0.009, respectively). The mutations of rs2107301-C and rs2189480-C alleles were associated with reduced sepsis risk. Haplotype C-C-C-C-C-T-C-A-G in the VDR gene was significantly associated with a 0.59-fold decreased risk of sepsis (95% CI: 0.12-0.76, p: 0.02). In the haplotype-phenotype analysis, significant association was noted for high-density lipoprotein, even after simulation correction (psim <0.05). CONCLUSIONS Taken together, our findings indicate that the VDR gene may be a sepsis-susceptibility gene in Chinese Han children.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34689148 PMCID: PMC8552509 DOI: 10.12659/MSM.932518
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The baseline characteristics of study children.
| Characteristics | Cases | Controls |
|---|---|---|
| Sample size | 267 | 283 |
| Age (months) | 29±35 | 45±38 |
| Sex, N (%) | 182 (68%) | 149 (53%) |
| TG (mmol/L) | 1.4 (1.0–2.0) | 0.8 (0.6–1.0) |
| HDL (mmol/L) | 0.7 (0.5–1.0) | 1.4 (1.1–1.6) |
| LDL (mmol/L) | 1.9 (1.3–2.4) | 2.2 (1.9–2.7) |
| AMY (U/L) | 26 (10–46) | 55 (37–74) |
| LD (U/L) | 415 (306–746) | 229 (207–253) |
| HBDH (mmol/L) | 290 (215–463) | 169 (150–189) |
| CKMB (IU/L) | 19 (7–31) | 22 (18–25) |
| Urea (mmol/L) | 3.4 (2.5–5.1) | 3.8 (3.1–4.6) |
| ALB (g/L) | 34 (30–38) | 44 (41–46) |
| ALP (U/L) | 129 (92–177) | 196 (158–241) |
| WBC (109/L) | 16 (11–23) | 7.2 (5.8–8.6) |
| RBC (109/L) | 4.0 (3.5–4.5) | 4.6 (4.3–4.9) |
| HGB (mmol/L) | 110 (95–124) | 126 (121–135) |
| PLT (mmol/L) | 300 (210–428) | 296 (236–337) |
TG – triglyceride; HDL – high-density lipoprotein; LDL – low-density lipoprotein; AMY – amylase; LD – lactate dehydrogenase; HBDH – hydroxybutyrate dehydrogenase; CKMB – creatine phosphokinase-Mb; ALB – albumin; ALP – alkaline phosphatase; WBC – white blood cell; RBC – red blood cell; HGB – hemoglobin; PLT – platelets. Data are expressed as mean±standard deviation or median (interquartile range) or number (%), where appropriate. The p was calculated using the t-test or Mann-Whitney U test or χ2 test, where appropriate.
p<0.05 between cases and controls.
Genotype and allele distributions of VDR gene 9 studied variants between cases and controls, and genotype-based risk prediction for sepsis mortality risk.
| Variants | Cases (n=267) | Controls (n=283) | OR, 95% CI, | ||
|---|---|---|---|---|---|
| rs9729 | CC | 133 (52%) | 144 (53%) | 0.98 | Reference group |
| AC | 104 (41%) | 112 (41%) | 1.05, 0.72–1.52, 0.81 | ||
| AA | 18 (7%) | 18 (6%) | 1.13, 0.55–2.31, 0.74 | ||
| A | 27% | 27% | 0.87 | ||
| rs2107301 | TT | 154 (59%) | 135 (48%) | 0.01 | Reference group |
| TC | 95 (36%) | 121 (43%) | 0.70, 0.48–1.01, 0.06 | ||
| CC | 12 (5%) | 26 (9%) | 0.44, 0.21–0.92, 0.03 | ||
| C | 23% | 31% | 0.003 | ||
| rs2189480 | AA | 137 (52%) | 109 (39%) | 0.004 | Reference group |
| CA | 106 (40%) | 137 (49%) | 0.62, 0.43–0.90, 0.01 | ||
| CC | 19 (8%) | 35 (12%) | 0.43, 0.23–0.81, 0.009 | ||
| C | 27% | 37% | 0.001 | ||
| rs2239185 | CC | 135 (51%) | 154 (55%) | 0.32 | Reference group |
| CT | 108 (41%) | 115 (41%) | 1.11, 0.77–1.59, 0.59 | ||
| TT | 20 (8%) | 13 (5%) | 1.94, 0.91–4.14, 0.09 | ||
| T | 28% | 25% | 0.24 | ||
| rs3782905 | CC | 192 (80%) | 195 (75%) | 0.20 | Reference group |
| CG | 48 (20%) | 60 (23%) | 0.83, 0.53–1.31, 0.43 | ||
| GG | 1 (0.4%) | 5 (2%) | 0.26, 0.03–2.39, 0.23 | ||
| G | 11% | 13% | 0.13 | ||
| rs4516035 | TT | 249 (95%) | 267 (96%) | 0.41 | Reference group |
| CT | 14 (5%) | 10 (4%) | 1.62, 0.66–3.94, 0.29 | ||
| CC | 0 (0%) | 1 (0.4%) | Unavailable | ||
| C | 3% | 2% | 0.59 | ||
| rs7139166 | CC | 248 (95%) | 271 (96%) | 0.54 | Reference group |
| CG | 14 (5%) | 11 (4%) | 1.52, 0.64–3.63, 0.35 | ||
| GG | 0 (0%) | 1 (0.4%) | Unavailable | ||
| G | 3% | 2% | 0.69 | ||
| rs11168266 | GG | 135 (52%) | 149 (53%) | 0.72 | Reference group |
| GA | 104 (40%) | 105 (38%) | 1.15, 0.79–1.68, 0.45 | ||
| AA | 20 (8%) | 26 (9%) | 0.89, 0.46–1.70, 0.72 | ||
| A | 28% | 28% | |||
| rs11168293 | GG | 250 (96.53%) | 272 (96.80%) | 0.86 | Reference group |
| GT | 9 (3%) | 9 (3%) | 1.24, 0.46–3.35, 0.68 | ||
| TT | 0 (0%) | 0 (0%) | Unavailable | ||
| T | 3% | 3% | 0.93 |
OR – odds ratio; 95% CI – 95% confidence interval. The p values were calculated after adjusting for age and sex in a logistic regression analysis.
The unadjusted and adjusted risk prediction of 9 studied variants for sepsis mortality risk under additive and dominant models, respectively.
| Variants | Model | Additive model | Dominant model |
|---|---|---|---|
| rs9729 | Unadjusted | 1.02, 0.78–1.35, 0.87 | 1.02, 0.72–1.43, 0.93 |
| Adjusted | 1.06, 0.79–1.40, 0.71 | 1.06, 0.74–1.51, 0.76 | |
| rs2107301 | Unadjusted | 0.66, 0.50–0.87, 0.003 | 0.64, 0.45–0.90, 0.01 |
| Adjusted | 0.68, 0.51–0.91, 0.008 | 0.65, 0.46–0.93, 0.02 | |
| rs2189480 | Unadjusted | 0.64, 0.49–0.83, 0.001 | 0.58, 0.41–0.81, 0.002 |
| Adjusted | 0.64, 0.49–0.84, 0.001 | 0.58, 0.41–0.83, 0.003 | |
| rs2239185 | Unadjusted | 1.19, 0.90–1.56, 0.23 | 1.14, 0.82–1.60, 0.44 |
| Adjusted | 1.24, 0.93–1.65, 0.15 | 1.19, 0.84–1.69, 0.33 | |
| rs3782905 | Unadjusted | 0.74, 0.50–1.09, 0.13 | 0.77, 0.50–1.17, 0.21 |
| Adjusted | 0.77, 0.51–1.17, 0.22 | 0.79, 0.51–1.24, 0.31 | |
| rs4516035 | Unadjusted | 1.23, 0.57–2.62, 0.60 | 1.37, 0.61–3.06, 0.45 |
| Adjusted | 1.34, 0.59–3.01, 0.48 | 1.49, 0.62–3.55, 0.37 | |
| rs7139166 | Unadjusted | 1.16, 0.55–2.45, 0.70 | 1.28, 0.58–2.81, 0.55 |
| Adjusted | 1.28, 0.58–2.84, 0.55 | 1.41, 0.60–3.30, 0.43 | |
| rs11168266 | Unadjusted | 0.99, 0.76–1.28, 0.93 | 1.05, 0.75–1.47, 0.80 |
| Adjusted | 1.02, 0.78–1.34, 0.87 | 1.10, 0.77–1.56, 0.60 | |
| rs11168293 | Unadjusted | 1.09, 0.43–2.79, 0.86 | 1.09, 0.43–2.79, 0.86 |
| Adjusted | 1.24, 0.46–3.35, 0.68 | 1.24, 0.46–3.35, 0.68 |
Data are expressed as odds ratio, 95% confidence interval, p value. The p values were calculated after adjusting for age and sex in a logistic regression analysis.
Haplotype frequencies (>1% in all cases and controls) of variants in VDR genes between cases and controls, and haplotype-based risk prediction for sepsis mortality risk.
| Haplotype | All | Cases | Controls | Hap-Score | P | Psim | OR (95% CI, P) |
|---|---|---|---|---|---|---|---|
| C-T-A-C-C-T-C-G-G | 0.44 | 0.46 | 0.41 | 2.16 | 0.03 | 0.04 | Ref. |
| A-T-A-T-C-T-C-A-G | 0.18 | 0.20 | 0.17 | 1.15 | 0.25 | 0.27 | 1.03 (0.70–1.50, 0.25) |
| C-C-C-C-G-T-C-G-G | 0.10 | 0.09 | 0.11 | −1.48 | 0.14 | 0.15 | 0.65 (0.41–1.02, 0.14) |
| C-C-C-C-C-T-C-G-G | 0.06 | 0.05 | 0.07 | −1.21 | 0.23 | 0.26 | 0.60 (0.33–1.12, 0.23) |
| C-T-C-C-C-T-C-G-G | 0.06 | 0.05 | 0.06 | −0.71 | 0.48 | 0.52 | 0.76 (0.42–1.36, 0.48) |
| A-C-C-T-C-T-C-A-G | 0.04 | 0.04 | 0.04 | −0.37 | 0.71 | 0.65 | 0.86 (0.41–1.81, 0.71) |
| C-C-C-C-C-T-C-A-G | 0.03 | 0.01 | 0.04 | −2.32 | 0.02 | 0.03 | 0.31 (0.12–0.76, 0.02) |
| C-C-A-C-C-T-C-G-G | 0.02 | 0.03 | 0.02 | 0.68 | 0.50 | 0.54 | 1.30 (0.51–3.33, 0.50) |
| A-T-C-T-C-T-C-A-G | 0.01 | 0.01 | 0.02 | −0.87 | 0.38 | 0.39 | 0.53 (0.11–2.62, 0.38) |
Hap-Score – haplotype score, Psim – simulated p value; OR – odds ratio; 95% CI – 95% confidence interval.
Alleles in each haplotype were in order of rs9729, rs2107301, rs2189480, rs2239185, rs3782905, rs4516035, rs7139166, rs11168266 and rs11168293 polymorphisms.
Global testing of all haplotypes with anthropometric index and clinical biomarkers.
| Characteristics | Global statistics | P | Psim |
|---|---|---|---|
| Age (month) | 14.05 | 0.93 | 0.77 |
| TG (mmol/L) | 12.35 | 0.93 | 0.77 |
| HDL (mmol/L) | 69.56 | <0.001 | 0.02 |
| LDL (mmol/L) | 15.12 | 0.82 | 0.69 |
| AMY (U/L) | 5.92 | 1.00 | 0.82 |
| LD (U/L) | 6.76 | 0.99 | 0.77 |
| HBDH (mmol/L) | 9.00 | 0.99 | 0.82 |
| CKMB (IU/L) | 5.30 | 1.00 | 0.75 |
| Urea (mmol/L) | 27.26 | 0.25 | 0.22 |
| ALB (g/L) | 3.98 | 1.00 | 0.69 |
| ALP (U/L) | 30.94 | 0.12 | 0.18 |
| WBC (109/L) | 10.99 | 0.98 | 0.79 |
| RBC (109/L) | 19.02 | 0.70 | 0.60 |
| HGB (mmol/L) | 23.01 | 0.46 | 0.37 |
| PLT (mmol/L) | 27.04 | 0.25 | 0.27 |
TG – triglyceride; HDL – high-density lipoprotein; LDL – low-density lipoprotein; AMY – amylase; LD – lactate dehydrogenase; HBDH – hydroxybutyrate dehydrogenase; CKMB – creatine phosphokinase-Mb; ALB – albumin; ALP – alkaline phosphatase; WBC – white blood cell; RBC – red blood cell; HGB – hemoglobin; PLT – platelets.
Figure 1The interaction of 9 variants under study in predisposition to pediatric sepsis.
DNA extraction procedure.
|
Preparation of samples: Pipet 200 μl sample to the microcentrifuge tube. If the volume is less than 200 μl, adjust volume to 200 μl with buffer GA. If the sample volume is more than 200 μl, e.g.300 μl-1ml, please refer the following step: add 3 times volume Red Cell Lysis Buffer to the sample, then invert the tube and close the cap. Stay the tube in room temperature (15–25°C) for 5min, and centrifuge at 12,000 rpm (~13,400×g) for 1 min, then discard the flow-through and pipet 200 μl buffer GA and mix by pulse-vortexing. Add 20 μl Proteinase K, mix thoroughly by vortexing. If the sample is tissue: incubate at 56°C until the tissue is completely lysed. Add 200 μl Buffer GB to the sample, mix thoroughly by vortexing, and incubate at 70°C for 10 min to yield a homogeneous solution. Briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from the inside of the lid. Add 200μl ethanol (96–100%) to the sample, and mix thoroughly by vortexing for 15 s. A white precipitate may form on addition of ethanol. Briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from the inside of the lid. Pipet the mixture from step 4 into the TIANamp Spin Column CB3 (in a 2 ml collection tube) and centrifuge at 12,000 rpm(~13,400×g) for 30s. Discard flow-through and place the spin column into the collection tube. Add 500 μl Buffer GD to TIANamp Spin Column CB3, and centrifuge at 12,000 rpm (~13,400×g) for 30s, then discard the flow-through and place the spin column into the collection tube. Add 700μl Buffer PW to TIANamp Spin Column CB3, and centrifuge at 12,000 rpm (~13,400×g) for 30s. Discard the flow-through and place the spin column into the collection tube. Add 500μl Buffer PW to TIANamp Spin Column CB3, and centrifuge at 12,000 rpm (~13,400×g) for 30s. Discard the flow-through and place the spin column into the collection tube. Centrifuge at 12,000 rpm (~13,400×g) for 2 min to dry the membrane completely. Place the TIANamp Spin Column CB3 in a new clean 1.5 ml microcentrifuge tube, and pipet 50–200 μl Buffer TE or distilled water directly to the center of the membrane. Incubate at room temperature (15–25°C) for 2–5 min, and then centrifuge for 2 min at 12,000 rpm (~13,400×g). |
Primers involved in the experiment.
| Rs number | Primer name | Primer sequences | Tm (°C) | Product length (bp) |
|---|---|---|---|---|
| rs9729 | VDR-P1-F | CCTTGCACCTGCATCCGTAG | 60 | 856 |
| VDR-P1-R | GAAAAGGACACCGGACCATGA | |||
| rs2107301 | VDR-P2-F | CTGTGCCGTTCATTTGGA | 60 | 284 |
| VDR-P2-R | AGTGTTGGGCTGTCTGGT | |||
| rs2189480 | VDR-P3-F | AGAGAGCAGCTGAGGCAATG | 60 | 415 |
| VDR-P3-R | GGACACCATTACGCTCTGGA | |||
| rs2239185 | VDR-P4-F | TCATTGCCATTTCCATAC | 60 | 387 |
| VDR-P4-R | GACATTTACACCCTCCTCT | |||
| rs3782905 | VDR-P5-F | GACAGATGGTCCTTTCTT | 58 | 693 |
| VDR-P5-R | AATCCACTACCCACTACA | |||
| rs4516035 | VDR-P6-F | GATGGCTGCGGAAAACTCAC | 60 | 470 |
| VDR-P6-R | ATTGAGTTGTGAGGGGCTGG | |||
| rs7139166 | VDR-P7-F | AGGCATAGCGTTTGATTG | 58 | 212 |
| VDR-P7-R | GGTATTGGTGGTTGGAAA | |||
| rs11168266 | VDR-P8-F | TTTCACCATAGCAAACCCAA | 60 | 391 |
| VDR-P8-R | CTCCCAGCAGGCAGACAT | |||
| rs11168293 | VDR-P9-F | ACCAAGGAACCCTGAGAC | 60 | 481 |
| VDR-P9-R | GAAGGCAAATAGGAAACAAT |